Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate ...
Two mRNA vaccines from Pfizer and Moderna are nearing final approval, and both work by rewiring a genetic trigger. SARS-CoV-2, the virus that causes COVID-19 (coronavirus), has a unique physical structure that can be used to prime immune response. An mRNA vaccine has never been approved ...
BEIJING, June 16 (Xinhua) -- A China-developed mRNA COVID-19 vaccine as a third booster dose has been shown in human trials to be safe and able to induce an immune response against the Omicron variant. AWcorna, previously known as ARCoV, which encodes the receptor-binding domain of SARS...
标题(英文):Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study 标题(中文):美国大型综合医疗系统中mRNA BNT162b2新冠疫苗接种后6个月内的有效性:一项回顾性队列研究 发表期刊:THE LANCET 作者单位:美国加利福尼亚...
美国于2022年9月1日建议12岁及以上儿童和青少年接种二价mRNA Covid-19疫苗,于2022年10月12日建议5至11岁儿童接种二价mRNA Covid-19疫苗。然而,证明二价Covid-19疫苗有效性的数据有限。 目的 评估二价CoVID-19疫苗对儿童和青少年中SARS-CoV-2感染和有症状的CoVID-19的有效性。
A medical worker injects a dose of COVID-19 vaccine at a vaccination site of Jingcheng Hospital in Ruili City, southwest China's Yunnan Province, April 1, 2021. (Xinhua/Chen Xinbo) BEIJING, Jan. 26 (Xinhua) -- A China-developed mRNA COVID-19 vaccine has been shown to be safe, well...
Last June, health authorities in France authorized a fourth COVID-19 mRNA vaccine dose for solid organ transplant recipients who had not adequately
A preliminary network analysis highlights the complex intellectual property landscape behind mRNA-based COVID-19 vaccines.
文章《乳腺癌重磅炸弹》披露了爆炸性信息:注射COVID(新冠)疫苗后,45 岁以下美国女人的乳腺癌病例急剧增加:从2019-2021年的年平均26,000例增加到2023年的297,000例,比疫苗注射前三年平均数增加了10.4倍。mRNA的COVID疫苗是世界上最危险的致命纳米粒子刺突朊病毒基因突变剂。
WHO announced that Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia will be part of a project that aims to enable low-and middle-income countries to manufacture mRNA vaccines in line with international standards. The project also intends to reduce Africa's reliance on vaccine manufacturers...